Vera Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Vera Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026, with key proposals including director elections and auditor ratification.
NASDAQ
Vera Therapeutics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
Vera Therapeutics sets its 2025 Annual Meeting for May 14, outlining proposals for director elections, auditor ratification, executive compensation, and vote frequency.
NASDAQ
DEFA14A: Vera Therapeutics Amends Non-Employee Director Compensation Policy, Reducing Equity Award Sizes
Vera Therapeutics has amended its non-employee director compensation policy to reduce the size of equity awards granted to non-employee directors.
NASDAQ
Vera Therapeutics, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
Vera Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on May 15, 2024, featuring the election of directors and ratification of the company's independent accounting firm.